The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass

Perfusion

Volumn 11, Issue 3, 1996, Pages 278-280

  Ali, M ^a   Becket, J ^a   Brannan, J ^a   Fleming, J ^a   Taylor, K M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ANIMAL EXPERIMENT; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MEGADOSE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029842441     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100314     Document Type: Conference Paper

References (14)

1. Wachtfogel YT, Kucich U, Greenplate J et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-30.
2. Gnanadurai TV, Branthwaite MA, Colbeck JF, Welman E. Lysosomal enzyme release during cardiopulmonary bypass. Anaesthesia 1977; 32: 743-48.
3. Bolanowski PJ, Bauer J, Machiedo G, Neville WE. Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1977; 73: 221-24.
4. Wachtfogel YT, DeLa Cadena RA, Colman RW. Structural biology, cellular interactions and pathophysiology of the contact system. Thromb Res 1993; 72: 1-21.
5. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-Cl-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-71.
6. Katz W, Mammen EF, Thal AP. Inhibition of fibrinolysis during extracorporeal circulation. Surg Forum 1965; 16: 63-64.
7. Nagaoka H, Innami R, Murayama F et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg Torino 1991; 32: 31-37.
8. Lu H, Soria C, Commin PL et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-37.
9. de Smet AA, Joen MC, van Oeveren W et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990; 100: 520-27.
10. Dietrich W, Spannagl M, Jochum M et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization Anesthesiology 1990; 73: 1119-26.
11. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass J Thorac Cardiovasc Surg 1991; 101: 958-67.
12. Nagaoka H, Katori M. Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery. Circulation 1975; 52: 325-32.
13. van Oeveren W, Jansen NJ, Bidstrup BP et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640-45.
14. Wachtfogel YT, Kucich U, Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9; discussion 9-10.